Landscapes / Targets

ALK

13 drugs act on ALK, in 33 active trials · Any stage · updated 18 Nov 2026

FollowEvery change as it happens, and a Monday email

Drugs13

DrugHow it worksCompanyStageNext dateDetails
ALK inhibitor
Roche · Public ROG.SW
Approved 30 Nov 2026soonPhase 2 trial completes
Tyrosine kinase inhibitor
Roche · Public ROG.SW
Approved 30 Nov 2026soonPhase 2 trial completes
ALK/ROS1 inhibitor
Pfizer · Public PFE
Approved 31 Dec 2026Phase 3 trial completes
ROS1/TRK/ALK inhibitor
Bristol Myers Squibb · Public BMY
Approved 16 Feb 2027Phase 3 trial completes
Kinase inhibitor
Novartis · Public NVS
Approved 9 Jun 2027Phase 4 trial completes
ALK inhibitor
Xcovery +1
Approved 1 Feb 2029Phase 1/2 trial completes
ALK inhibitor
Phase 3 Dec 2027Phase 1/2 trial completes
ALK/ROS1 inhibitor
Phase 3 —
ALK7 siRNA
Arrowhead · Public ARWR
Phase 1/2 Feb 2027Phase 1/2 trial completes
—
Phase 2 Dec 2027Phase 1/2 trial completes
—
Phase 1/2 31 May 2029Phase 1/2 trial completes
—
Phase 1 May 2027Phase 1 trial completes
—
Phase 1 1 Dec 2028Phase 1 trial completes

About this list

Checked
13 of 13 drugs. How we check
Matches
The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
Sources
ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ALK

Following is part of Solo: you see every change to ALK the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in